Transdermal science

Beyond dermatology.

The physics that gets an active to the dermis can, with the right drug and dose, carry it into the circulation. That opens cream-based alternatives to tablets and patches in pain, hormones and replacement therapy.

01 From dermal to systemic

One platform, two destinations

Answer first

Dermal delivery stops in the skin, while transdermal delivery continues into the bloodstream. Both must cross the stratum corneum, which favours small, potent, moderately lipophilic drugs. Cetylated nanovesicles fit both because they cross the barrier without lasting disruption and release gradually. The patent explicitly covers delivery for local or systemic applications.

Transdermal delivery generations and constraints [1]; molecular size limit[4]; systemic examples [2]; foundational penetrant platform[3].

02 Application 01

Pain management topicals

Answer first

Topical NSAIDs act locally with far lower systemic exposure than oral dosing, but they depend on getting enough drug through the barrier. The cetosome patent reports a Phase 2 study of 100 patients with chronic discogenic back pain using an analgesic cetosome composition, with sustained relief lasting several hours after application.

Evidence & status

  • Diclofenac and ketoprofen formulation examples are described in the patent[2]
  • Ketoprofen absorption tested in 8 volunteers aged 24–35[2]
  • Diclofenac plasma levels remained below 100 ng/mL in the dosing evaluation[2]

03 Application 02

Hormone replacement therapy

Answer first

Transdermal hormones avoid first-pass liver metabolism and give steadier plasma levels than oral tablets. Gels and patches are standard, but adhesive irritation and inconsistent absorption limit them. A water-rich, barrier-compatible vesicle vehicle with controlled release is an obvious research direction. Steroid hormones appear in the patent's list of candidate actives.

Evidence & status

  • Estradiol and testosterone are listed as candidate bioactives[2]
  • Avoids the skin irritation of patch adhesives[2]
  • Requires dedicated pharmacokinetic and regulatory development[2]

04 Application 03

Patch-replacement systems

Answer first

Transdermal patches deliver small, potent drugs such as nicotine and anticholinergics, but adhesive dermatitis, visible patches and fixed dosing push patients away. A cream that gives patch-like steady plasma levels is the alternative being explored. In the patent's rabbit study, oxybutynin peaked at 6 hours and stayed at useful levels for most of the day.

Evidence & status

  • Rabbit PK study (n = 3 per dose): oxybutynin Cmax at 6 h; above 2 ng/mL for most of 24 h[2]
  • Feasibility also shown for tolterodine and trospium[2]
  • Potential application to cessation and replacement regimens[2]

R&D note

Active research, not yet a product claim

These extensions are at the research and development stage. Systemic drugs need dedicated pharmacokinetic studies, dose finding and regulatory approval before clinical use. Nothing on this page is a treatment recommendation.

On the clinical-dermatology side, the Monoskin research team is actively exploring these transdermal extensions of the Cetosome® platform with its pharmaceutical development partners.

Frequently asked

Can cetosomes deliver drugs through the skin into the bloodstream?

Yes, in principle. The patent describes compositions that deliver drugs into or through the skin for local or systemic effect. Its examples include a rabbit pharmacokinetic study in which oxybutynin plasma levels stayed above 2 ng/mL for most of 24 hours, and ketoprofen absorption testing in eight human volunteers.

What is the difference between dermal and transdermal delivery?

Dermal delivery targets the skin itself, for example acne, pigmentation or barrier repair. Transdermal delivery moves a drug through the skin into the systemic circulation, as nicotine and hormone patches do. Both must cross the stratum corneum, which limits which drugs qualify.


References

  1. Prausnitz MR, Langer R. Transdermal drug delivery. Nature Biotechnology 26(11):1261–1268. 2008.DOI 10.1038/nbt.1504
  2. Barathur RR, Bookout JB (assignee: Cymbiotics, Inc.). Topical dermal delivery compositions using self assembling nanoparticles with cetylated components. US Patent US 9,084,818 B2. 2015.Filed 15 Feb 2013; granted 21 Jul 2015. Claim 1 specifies nanoparticle zeta potential of −20 to −100 mV (or +20 to +100 mV). Measured particle diameters of 60–850 nm; claimed physical dimensions 30 nm–5 µm.
  3. Barathur RR, Bookout JB (assignee: Cymbiotics, Inc.). Transdermal delivery of medicaments with combinations of cetylated fatty ester penetrant complexes. US Patent US 8,394,759 B2. 2013.Priority 21 Nov 2008; filed 29 Oct 2009; granted 12 Mar 2013. Foundational cetylated-fatty-ester penetrant work, incorporated by reference into US 9,084,818 B2.
  4. Bos JD, Meinardi MMHM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology 9(3):165–169. 2000.DOI 10.1034/j.1600-0625.2000.009003165.x

Methodology

Content is written from primary sources: granted US patent text, peer-reviewed journals indexed in PubMed or Crossref, and regulator publications. Numerical specifications are quoted exactly as reported in the cited source. Where data are illustrative models rather than measurements, the figure says so.

Conflict of interest & scope

Cetosomes.com is operated in association with parties that manufacture and dispense Cetosome®-based formulations. This site explains vehicle and delivery biophysics; it does not diagnose, treat or prescribe. Clinical decisions belong to a qualified dermatologist or physician. Research articles in the Journal carry no product or brand references.

In your routine or your clinic

Explore Cetosome® formulations

Cetosome® vehicles are dispensed through dermatology, not mass retail. The direct way to bring the technology into your routine or practice is Monoskin, the dermatological range built on the platform.

For your skin: choose a need

For your clinic

Stocking or prescribing Cetosome® formulations? Reach the clinic team, or ask our formulation desk for the literature dossier.

Opens monoskin.com in a new tab. Diagnosis and the choice of active belong to your dermatologist.